Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 3/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 3/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3695512 | 0.92 | CCR1 (0.35) | ACP3CNR2P2RX7SLC6A4AR | |
| SCHEMBL909422 | 0.92 | CCR1 (0.35) | ACP3CNR2P2RX7SLC6A4AR | |
| SCHEMBL720614 | 0.84 | ACP3 (0.39) | ACP3CNR2P2RX7SLC6A4AR | |
| SCHEMBL28776287 | 0.84 | CTSK (0.37) | ACP3CNR2P2RX7SLC6A4AR | |
| SCHEMBL15103290 | 0.80 | AR (0.35) | AR | |
| SCHEMBL7909506 | 0.80 | CYP1A2 (0.37) | ACP3CNR2P2RX7SLC6A4AR | |
| SCHEMBL7906628 | 0.80 | ACP3 (0.36) | ACP3CNR2SLC6A4ARMC4R | |
| SCHEMBL21631985 | 0.80 | CNR2 (0.45) | ACP3CNR2CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL3692370 | 0.80 | ACP3 (0.36) | ACP3CNR2SLC6A4ARMC4R | |
| SCHEMBL1096034 | 0.80 | ACP3 (0.41) | ACP3CNR2P2RX7SLC6A4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754100-B2 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| EP-2615090-A1 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-2401276-B1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2401276-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | Eisai R&D Management Co., Ltd. (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110172427-A1 | PROCESS FOR PREPARING CERTAIN CINNAMIDE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| WO-2010098487-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172427-A1 | PROCESS FOR PREPARING CERTAIN CINNAMIDE COMPOUNDS | CYP4A11, CYP51A1, NISCH | ACP3 2364/4885CNR2 417/4885P2RX7 492/4885 |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | APP, BACE1, PSEN1 | ACP3 3500/4885CNR2 232/4885P2RX7 1890/4885 |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | BACE1, APP, PSEN1 | ACP3 4278/4885CNR2 2884/4885P2RX7 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.